These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 9620920)
21. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Liu YM; Cheng YJ; Li YL; Liu CE; Hsu WH Lung; 2014 Feb; 192(1):205-10. PubMed ID: 24292367 [TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity. Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M Indian J Med Res; 2016 Dec; 144(6):924-928. PubMed ID: 28474630 [TBL] [Abstract][Full Text] [Related]
23. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. Padmapriyadarsini C; Chandrabose J; Victor L; Hanna LE; Arunkumar N; Swaminathan S J Postgrad Med; 2006; 52(2):92-6. PubMed ID: 16679670 [TBL] [Abstract][Full Text] [Related]
24. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542 [TBL] [Abstract][Full Text] [Related]
26. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986 [TBL] [Abstract][Full Text] [Related]
27. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Satyaraddi A; Velpandian T; Sharma SK; Vishnubhatla S; Sharma A; Sirohiwal A; Makharia GK; Sinha S; Biswas A; Singh S Int J Tuberc Lung Dis; 2014 Feb; 18(2):188-95, i-iii. PubMed ID: 24429311 [TBL] [Abstract][Full Text] [Related]
28. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Lima Mde F; Melo HR Cad Saude Publica; 2012 Apr; 28(4):698-708. PubMed ID: 22488315 [TBL] [Abstract][Full Text] [Related]
29. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037 [TBL] [Abstract][Full Text] [Related]
30. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Mo P; Zhu Q; Teter C; Yang R; Deng L; Yan Y; Chen J; Zeng J; Gui XE Int J Infect Dis; 2014 Nov; 28():95-100. PubMed ID: 25218771 [TBL] [Abstract][Full Text] [Related]
31. Management of antitubercular drugs-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal. Shakya R; Rao BS; Shrestha B Kathmandu Univ Med J (KUMJ); 2005; 3(1):45-9. PubMed ID: 16401944 [TBL] [Abstract][Full Text] [Related]
32. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Wong WM; Wu PC; Yuen MF; Cheng CC; Yew WW; Wong PC; Tam CM; Leung CC; Lai CL Hepatology; 2000 Jan; 31(1):201-6. PubMed ID: 10613746 [TBL] [Abstract][Full Text] [Related]
33. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. de Castro L; do Brasil PE; Monteiro TP; Rolla VC Int J Tuberc Lung Dis; 2010 Mar; 14(3):332-40. PubMed ID: 20132625 [TBL] [Abstract][Full Text] [Related]
34. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. Kuaban C; Bercion R; Koulla-Shiro S East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410 [TBL] [Abstract][Full Text] [Related]
35. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691 [TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Chien JY; Huang RM; Wang JY; Ruan SY; Chien YJ; Yu CJ; Yang PC Int J Tuberc Lung Dis; 2010 May; 14(5):616-21. PubMed ID: 20392356 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India. Saha A; Shanthi F X M; Winston A B; Das S; Kumar A; Michael JS; Balamugesh T J Prim Care Community Health; 2016 Jul; 7(3):171-4. PubMed ID: 27056794 [TBL] [Abstract][Full Text] [Related]
38. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Makhlouf HA; Helmy A; Fawzy E; El-Attar M; Rashed HA Hepatol Int; 2008 Sep; 2(3):353-60. PubMed ID: 19669265 [TBL] [Abstract][Full Text] [Related]
39. Tolerability of anti-tuberculosis treatment and HIV serostatus. Lanternier F; Dalban C; Perez L; Bricaire F; Costagliola D; Caumes E Int J Tuberc Lung Dis; 2007 Nov; 11(11):1203-9. PubMed ID: 17958982 [TBL] [Abstract][Full Text] [Related]
40. Impact of chronic renal failure on anti-tuberculosis treatment outcomes. Baghaei P; Marjani M; Tabarsi P; Moniri A; Rashidfarrokhi F; Ahmadi F; Nassiri AA; Masjedi MR; Velayati AA; Cattamanchi A Int J Tuberc Lung Dis; 2014 Mar; 18(3):352-6. PubMed ID: 24670575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]